Waylivra Market Report 2026

Waylivra Market Overview

• The Waylivra market growth in the historic period has been driven by improved diagnosis of rare lipid disorders, advancements in antisense oligonucleotide development • Market expansion is supported by increasing investments in genetic medicine research, rising adoption of targeted metabolic therapies • Growth Driver: Rising Prevalence Of Rare Genetic Disorders Driving Growth In The Market • Europe was the largest region in 2025.

What Is Covered Under Waylivra Market?

Waylivra (volanesorsen) is a medication used for a rare genetic disorder characterized by very high triglyceride levels. It works by inhibiting the production of ApoC-III, a protein that regulates triglyceride metabolism, helping to lower triglyceride levels and reduce the risk of related complications like pancreatitis. The main types of indications for waylivra are familial chylomicronemia syndrome, hypertriglyceridemia, and rare lipid disorders. Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by extremely high triglyceride levels in the blood, leading to an increased risk of pancreatitis and other complications. It is distributed through various distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies. Also, it is used by several end users, including adults and geriatrics.

What Is The Waylivra Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in genetic medicine research, rising adoption of targeted metabolic therapies, expansion of personalized lipid management approaches, growing focus on rare disease treatment accessibility, increasing integration of genomic diagnostics. Major trends in the forecast period include increasing adoption of rna-targeted therapies, rising focus on rare lipid disorder management, growing use of precision metabolic treatments, expansion of genetic disorder screening programs, enhanced monitoring of lipid metabolism outcomes.

Global Waylivra Market Segmentation

1) By Indication: Familial Chylomicronemia Syndrome, Hypertriglyceridemia, Rare Lipid Disorders 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies 3) By End User: Adult, Geriatric

What Are The Drivers Of The Waylivra Market?

The prevalence of rare genetic disorders is expected to propel the growth of the waylivra market going forward. Rare genetic disorders are conditions caused by mutations in a person's DNA, affecting many people. The prevalence of rare genetic disorders is due to advancements in genetic testing, better awareness, improved reporting, and more access to genetic screening and reproductive technologies. Waylivra treats rare genetic disorders by blocking a protein involved in lipid metabolism, which lowers blood. For instance, in May 2024, according to the National Health Service, a UK-based government department, in England, approximately 17,000 people live with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed each year. Therefore, the rising prevalence of rare genetic disorders drives the waylivra industry. The increasing healthcare expenditure is expected to propel the growth of the waylivra market going forward. Healthcare expenditure refers to the financial resources allocated to healthcare services, encompassing medical treatments, hospital care, pharmaceuticals, healthcare infrastructure, and preventive care. The rise in healthcare expenditure is attributed to the increasing demand for advanced medical treatments, the aging population, and the growing prevalence of chronic diseases. Rising healthcare expenditure supports the growth of waylivra by boosting the demand for cutting-edge healthcare technologies that improve patient care and streamline operations as healthcare providers invest in advanced solutions. For instance, in April 2025, according to the Office for National Statistics, a UK-based government agency reported that provisional estimates show UK healthcare spending reached £317 billion in 2024, growing 6.5% nominally and 2.4% in real terms from 2023. Total long-term care expenditure rose 3.1% in real terms in 2023, primarily due to increased government spending. Therefore, the increasing healthcare expenditure is driving the growth of the waylivra industry.

Key Players In The Global Waylivra Market

Major companies operating in the waylivra market are Akcea Therapeutics Inc.

What Are Latest Mergers And Acquisitions In The Waylivra Market?

In January 2024, Acino International AG, a Switzerland-based pharmaceutical company, partnered with Sobi. This collaboration involves an exclusive distribution agreement to commercialize several orphan drugs, including doptelet, aspaveli, gamifant, kineret, orfadin, tegsedi, and waylivra in Kazakhstan. Further, Acino will be responsible for marketing and commercializing Sobi’s products in the specialized hospital segment starting in early 2024. Sobi is a Sweden-based biopharmaceutical company.

Regional Insights

Europe was the largest region in the waylivra market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Waylivra Market?

The waylivra market consists of sales of syringes, injection supplies, and patient support programs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Waylivra Market Report 2026?

The waylivra market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the waylivra industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.